Nothing Special   »   [go: up one dir, main page]

WO2000012130A1 - Agonistes et antagonistes de rp105 - Google Patents

Agonistes et antagonistes de rp105 Download PDF

Info

Publication number
WO2000012130A1
WO2000012130A1 PCT/US1999/019336 US9919336W WO0012130A1 WO 2000012130 A1 WO2000012130 A1 WO 2000012130A1 US 9919336 W US9919336 W US 9919336W WO 0012130 A1 WO0012130 A1 WO 0012130A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
cells
polypeptide
cell
antibodies
Prior art date
Application number
PCT/US1999/019336
Other languages
English (en)
Inventor
Jeremy A. Harrop
Stephen D. Holmes
Amy K. Roshak
Original Assignee
Smithkline Beecham Corporation
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation, Smithkline Beecham Plc filed Critical Smithkline Beecham Corporation
Publication of WO2000012130A1 publication Critical patent/WO2000012130A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5052—Cells of the immune system involving B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Definitions

  • An object of this invention is to provide a method for treating or preventing allergic disease, including asthma and atopic dermatitis, B cell neoplasms, including chronic lymphocyte leukemia, hairy cell leukemia, prolymphocytic leukemia myelomas, autoimmune diseases such as systemic lupus Erythamatoss (SLE), rheumatoid arthritis(RA), Multiple Sclerosis (MS), aquired hemolytic anemia and diabetes, among others, in a mammal using an antagonist to RP105 receptor.
  • SLE systemic lupus Erythamatoss
  • RA rheumatoid arthritis
  • MS Multiple Sclerosis
  • aquired hemolytic anemia and diabetes among others, in a mammal using an antagonist to RP105 receptor.
  • Mature B cells comprise 10 to 15 percent of human peripheral blood lymphocytes, 50 percent of splenic lymphocytes, and approximately 10 percent of bone marrow lymphocytes.
  • Mature B cells are derived from bone marrow precursor cells that arise continuously throughout life. B cells express on their surface intramembrane immunoglobulin (Ig) molecules that function as B cell antigen receptors in a complex of Ig- associated a and p signaling molecules with intracellular signaling events. B cells also express surface receptors for the Fc region of IgG molecules as well as receptors for activated complement components. The primary function of B cells is to produce antibodies.
  • Ig immunoglobulin
  • B cells undergo several selection steps during differentiation from immature cells to mature B cells or antibody-secreting cells. Only B cells which have undergone the selection process join the mature B cell pool and differentiate into antibody secreting cells upon stimulation. These selections allow for maintenance of a stable B cell pool without the production of autoreactive B cells which react to create an autoimmune response and efficient antibody production with adequate specificity and affinity, von Boehmer, H. Cell 1994 76:210; Liu et al. Immunol. Today 1992 13:17; Liu et al. Nature (Lond.) 1989 342:929. The selection steps involve apoptosis, survival or proliferation of B cells.
  • apoptosis plays an essential role in the selection process.
  • a signal that is capable of inducing or blocking apoptosis has been implicated as a pivotal system for selecting B cells.
  • Lymphocytes such as B cells are one of the most sensitive cells to immediate radiation induced damage. Anderson, R.E., and Warner, N.L. Adv. Immunol. 1976 24:215. Quiescent lymphocytes have been found to be more sensitive than actively cycling cells. The damaged cells are believed to undergo apoptosis. This process, which does not involve cell division, is sometimes referred to as interphase death. It has been hypothesized that lymphocyte signaling systems which are important in facilitating the B cell selection process are also related to cell death by irradiation.
  • RP105 is a murine B cell antigen. It is monomeric, with a size of approximately 105 kDa. It is expressed on mature B cells, but not on either immature or pre-B cells. This antigen is believed to transmit a signal into murine B cells that results in protection from radiation or dexamethasone induced apoptosis.
  • the N-terminal amino acid sequence of the murine RP105 molecule has been determined.
  • a cDNA clone was also isolated with a probe corresponding to the obtained amino acid sequence.
  • DNA sequencing revealed that an encoded murine polypeptide is a type 1 transmembrane protein consisting of 641 amino acids in a mature form.
  • Northern hybridization with the clone detected a transcript of approximately 3 kb. This transcript was found in mouse spleen, but not thymus, kidney, muscle, heart, brain or liver. Transfection of the clone into a pro-B cell line resulted in the expression of RP105.
  • a computer search showed similarity of murine RP105 to a number of molecules including CD 14, decorin and biglycan, which are human proteoglycans in extracellular tissue; the Drosophila toll, tartan, connectin, chaoptin and slit proteins (which are responsible for dorsal/ventral polarity, epidermal/subepidermal structure, target recognition of a subset of motor neurons, photoreceptor morphogenesis and pathway finding by commissural axons during embryogenesis); and the a-subunit of platelet glycoprotein lb (involved in platelet adhesion to vascular endothelial cells).
  • CD 14 human proteoglycans in extracellular tissue
  • decorin and biglycan which are human proteoglycans in extracellular tissue
  • Drosophila toll, tartan, connectin, chaoptin and slit proteins which are responsible for dorsal/ventral polarity, epidermal/subepidermal structure, target recognition of a
  • murine RP105 The property shared by murine RP105 and these molecules is tandem repeats of a leucine-rich motif (LRM). These repeated motifs are observed in members of the leucine-rich repeat protein family and have been implicated in protein-protein interactions such as cell adhesion or receptor-ligand binding.
  • the murine RP105 molecule has 22 tandem repeats of a leucine-rich motif, as well as amino and carboxyl flanking regions that are characteristically conserved among members of this family. Thus, murine RP105 is believed to be a member of the leucine-rich repeat family and the first one that is expressed specifically on mature B cells.
  • the invention provides an anti-RP105 antibody.
  • the invention provides a composition comprising the anti-RP105 antibody and a pharmaceutically acceptable carrier, as well as a method for treating or preventing allergic disease, including asthma and atopic dermatitis, B cell neoplasms, including chronic lymphocyte leukemia, hairy cell leukemia, prolymphocytic leukemia, myelomas, autoimmune diseases such as systemic lupus Erythamatosus (SLE), rheumatoid arthritis(RA), Multiple Sclerosis (MS), aquired hemolytic anemia or diabetes; comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of anti-RP105 antibody or its composition.
  • allergic disease including asthma and atopic dermatitis
  • B cell neoplasms including chronic lymphocyte leukemia, hairy cell leukemia, prolymphocytic leukemia, myelomas, autoimmune diseases such as systemic lupus Erythamatosus (SLE), rheumato
  • FIGURES Figure 1 (A) Effect of RP105 antiserum on PBL proliferation and (B) levels of soluble CD23 in culture supernatants.
  • RP105 RP105 polypeptide
  • RP105 receptor is defined as a polypeptide which has at least 80% identity to a polypeptide of SEQ ID NO: 2.
  • the definitions includes any fragment of RP105 that can be used to raise antibodies against an RP105 epitope.
  • the definition covers any fragment of RP105 capable of functioning as an immunogen by itself or capable of functioning as an antigen in a conjugate created by the recombinant or in vitro fusion of the RP105 fragment and an immunogen.
  • RP105 also includes a polypeptide sequence defined as SEQ ID NO:4 disclosed in US patent no. 5,707,829 issued January 13, 1998, which is incorporated by reference in its entirety.
  • Identity is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences.
  • identity also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences.
  • Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, the GCG program package (Devereux, J., et al., Nucleic Acids Research 12(1): 387 (1984)), BLASTP, BLASTN, and FASTA (Atschul, S.F. et al., J. Molec. Biol.
  • the BLAST X program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S., et al., NCBI NLM NIH Bethesda, MD 20894; Altschul, S., et al., J. Mol. Biol. 215: 403-410 (1990).
  • the well known Smith Waterman algorithm may also be used to determine identity.
  • Preferred parameters for polypeptide sequence comparison include the following: 1) Algorithm: Needleman and Wunsch, J. Mol Biol. 48: 443-453 (1970) Comparison matrix: BLOSSUM62 from Hentikoff and Hentikoff, Proc. Natl. Acad. Sci. USA. 89: 10915-10919 (1992) Gap Penalty: 12 Gap Length Penalty: 4 A program useful with these parameters is publicly available as the "gap" program from Genetics Computer Group, Madison WL The aforementioned parameters are the default parameters for peptide comparisons (along with no penalty for end gaps).
  • a polynucleotide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:2, that is be 100% identical, or it may include up to a certain integer number of nucleotide alterations as compared to the reference sequence.
  • Such alterations are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence.
  • the number of nucleotide alterations is determined by multiplying the total number of nucleotides in SEQ ID NO:2 by the numerical percent of the respective percent identity(divided by 100) and subtracting that product from said total number of nucleotides in SEQ ID NO:2, or: n n ⁇ x n - ( ⁇ n • y), wherein n n is the number of nucleotide alterations, x n is the total number of nucleotides in SEQ ID NO:2, and y is, for instance, 0.70 for 70%, 0.80 for 80%, 0.85 for 85%, 0.90 for 90%, 0.95 for 95%,etc, and wherein any non-integer product of x n and y is rounded down to the nearest integer prior to subtracting it from x n .
  • Alterations of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:l may create nonsense, missense or frameshift mutations in this coding sequence and thereby alter the polypeptide encoded by the polynucleotide following such alterations.
  • a polypeptide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:l, that is be 100% identical, or it may include up to a certain integer number of amino acid alterations as compared to the reference sequence such that the % identity is less than 100%.
  • Such alterations are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non- conservative substitution, or insertion, and wherein said alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence.
  • the number of amino acid alterations for a given % identity is determined by multiplying the total number of amino acids in SEQ ID NO: 1 by the numerical percent of the respective percent identity(divided by 100) and then subtracting that product from said total number of amino acids in SEQ ID NO: 1, or: n a ⁇ ⁇ a - ( ⁇ a • y).
  • n a is the number of amino acid alterations
  • x a is the total number of amino acids in SEQ ID NO: l
  • y is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc., and wherein any non-integer product of x a and y is rounded down to the nearest integer prior to subtracting it from x a .
  • Anti-RP105 antibody is defined as any antibody that binds to an RP105 or fragment thereof.
  • the definition includes antibodies of all immunoglobulin types, such as IgG, IgA, IgM, IgD and IgE, and fragments thereof, such as Fab, F(ab')2, and Fv, and includes antibodies and antibody fragments of all origins, such as polyclonal antibodies, monoclonal antibodies, humanized antibodies and human antibodies produced in transgenic animals or transgenic animal cell culture.
  • blocking RP105 antibody means an antibody capable of blocking RP105.
  • “Highly stringent conditions” include overnight incubation at 42°C in a solution comprising: 50% formamide, 5xSSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10 % dextran sulfate, and 20 microgram/ml denatured, sheared salmon sperm DNA; followed by washing the filters in 0.1 x SSC at about 65°C.
  • RP105 for use in anti-RP105 antibody preparation can be isolated from natural sources or synthesized by in vitro or recombinant techniques. What follows is a description of each of these three methods of making RP105.
  • the RP105 or antigenic fragment thereof is produced by recombinant techniques.
  • the recombinant RP105 or fragment thereof can be used as immunogen without an adjuvant.
  • the immunogen is a fusion protein that contains the amino acid sequence of a suitable adjuvant fused to RP105.
  • the recombinant RP105 is covalently fused in vitro to an adjuvant or is administered concomitantly with an adjuvant.
  • recombinant cells expressing the RP105 as a surface protein anchored to the cell membrane are used to immunize the desired animal species. Recombinant cells expressing RP105 as cell surface protein will generate the desired immunogenic response in the animal without the use of an adjuvant.
  • All DNA sequences including the DNA sequence of SEQ ID NO:2, that encode a polypeptide within the amino acid sequence of SEQ ID NO: 1 are suitable for use in the recombinant production of RP105.
  • Additional DNA sequences suitable for use herein include a polynucleotide which has at least 80% identity to a polynucleotide which encode polypeptide of SEQ ID NO: 1.
  • sequences suitable for use also include any polypeptide-encoding DNA sequence that hybridizes under highly stringent conditions to the complement of the DNA sequence of SEQ ID NO: 2, or to the complement of any other DNA sequence encoding a polypeptide having the amino acid sequence of SEQ ID NO: 1.
  • candidate hybridizing DNA sequences can be obtained by designing DNA sequences that encode variants of the amino acid sequence of SEQ ID NO: 1.
  • variants include, for example, deletions from, or insertions and substitutions of, residues within the amino acid sequence of SEQ ID NO: 1. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct is encoded by a DNA sequence that hybridizes under highly stringent conditions to the complement of the DNA sequence of SEQ ID NO: 2, or to the complement of any other DNA sequence that encodes a polypeptide having the amino acid sequence of SEQ ID NOT .
  • host cells can be genetically engineered to incorporate expression systems or portions thereof for above-described polynucleotides.
  • Introduction of polynucleotides into host cells can be effected by methods described in many standard laboratory manuals, such as Davis et al., Basic Methods in Molecular Biology (1986) and Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989).
  • Preferred such methods include, for instance, calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.
  • bacterial cells such as streptococci, staphylococci, E. coli, Streptomyces and Bacillus subtilis cells
  • fungal cells such as yeast cells and Aspergillus cells
  • insect cells such as Drosophila S2 and Spodoptera Sf9 cells
  • animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells
  • plant cells include bacterial cells, such as streptococci, staphylococci, E. coli, Streptomyces and Bacillus subtilis cells
  • fungal cells such as yeast cells and Aspergillus cells
  • insect cells such as Drosophila S2 and Spodoptera Sf9 cells
  • animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells
  • expression systems can be used, for instance, chromosomal, episomal and virus-derived systems, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids.
  • the expression systems may contain control regions that regulate as well as engender expression.
  • any system or vector which is able to maintain, propagate or express a polynucleotide to produce a polypeptide in a host may be used.
  • the appropriate nucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook et al, MOLECULAR CLONING, A LABORATORY MANUAL (supra).
  • Appropriate secretion signals may be incorporated into the desired polypeptide to allow secretion of the translated protein into the lumen of the endoplasmic reticulum, the periplasmic space or the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals.
  • RP105 polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide. If produced intracellularly, the cells must first be lysed before the polypeptide is recovered.
  • Polypeptides of the present invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during isolation and or purification.
  • RP105 can also be produced by in vitro chemical synthesis.
  • the desired RP105 is constructed by the solid phase synthesis method described by Merrifield, Science, 232; 342- 347 (1986). In this method, a growing polypeptide chain is covalently anchored, usually by its C-terminus, to an insoluble solid support such as beads of polystyrene resm, and the appropriately blocked ammo acids and reagents are added in the proper sequence This permits the quantitative recovery of the desired peptide product by simply filtering and washing the beads It will be appreciated that any method of peptide synthesis now or hereafter developed can be used to synthesize RP105 for use in the present invention
  • Polyclonal antibodies to the RP105 generally are raised in animals by multiple subcutaneous (sc) or lntrape ⁇ toneal ( ) injections of the RP105 and an adjuvant Immunization with recombinant cells expressing the RP105 (e g mouse or CHO cells expressing RP105) may be satisfactory, or it may be useful to separate the RP105 and conjugate it or a fragment containing the amino acid sequence of the desired RP105 antigenic site to a protein that is immunogenic in the species to be immunized, e g , keyhole limpet hemocyamn, serum albumin, bovine thyroglobuhn, or soybean trypsm inhibitor using a bifunctional or denvatizing agent, for example, maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues), N-hydroxysuccinimide (through lysine residues), glutaraldehyde, succinic anhydride, SOC12,
  • Animals ordinarily are immunized against the cells or immunogenic conjugates of RP105 with monophosphoryl hpid A (MPL) ⁇ rehalose dicorynomycolate (TDM)(R ⁇ b ⁇ Immunochem, Research, Inc , Hamilton, Mont ) and injecting the solution intradermally at multiple sites Two weeks later the animals are boosted with the original amount of conjugate in MPL/TDM 7 to 14 days later animals are bled and the serum is assayed for ant ⁇ -RP105 titer Animals are boosted until the titer plateaus Preferably, the animal is boosted with the conjugate of the same RP105, but conjugated to a different protein and/or through a different cross-linking agent Conjugates also can be made in recombinant cell culture as protein fusions Also, aggregating agents such as alum are used to enhance the immune response
  • Monoclonal antibodies are prepared by recovering spleen cells from immunized animals and immortalizing the cells in conventional fashion, e g , by fusion with myeloma cells or by Epstein-Barr (EB)-v ⁇ rus transformation and screening for clones expressing the desired antibody
  • EB Epstein-Barr
  • the hyb ⁇ doma technique described originally by Koehler and Milstein, Eur J Immunol , 6 511 (1976) and also described by Hammerhng et al , In Monoclonal Antibodies and T-Cell Hyb ⁇ domas, Elsevier, N Y , pp 563-681 (1981) has been widely applied to produce hybrid cell lines that secrete high levels of monoclonal antibodies against many specific antigens
  • the hybrid cell lines can be maintained in vitro in cell culture media
  • the cell lines producing the antibodies can be selected and/or maintained m a medium containing hypoxanthine-aminopte ⁇ n thymidine (HAT)
  • HAT hypoxanthine-aminopte ⁇ n thymidine
  • the hybrid cell lines can be stored and preserved in any number of conventional ways, including freezing and storage under liquid nitrogen Frozen cell lines can be revived and cultured indefinitely with resumed synthesis and secretion of monoclonal antibody
  • the secreted antibody is recovered from tissue culture supernatant or ascites fluid by conventional methods such as immune precipitation, ion-exchange chromatography, affinity chromatography such as protein A/protein G column chromatography, or the like
  • the antibodies described herein are also recovered from hyb ⁇ doma cell cultures by conventional methods such as precipitation with 50% ammonium sulfate
  • the purified antibodies can then be sterile filtered
  • monoclonal antibody refers to an antibody obtained from a population of substantially homogeneous antibodies, 1 e , the individual antibodies comp ⁇ sing the population are identical except for possible naturally occurring mutations that may be present in minor amounts Monoclonal antibodies are highly specific, being directed against a single antigenic site Furthermore, in contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen In addition to their specificity, the monoclonal antibodies are advantageous in that they are synthesized by the hyb ⁇ doma culture, uncontaminated by other lmmunoglobulms
  • the monocolonal antibodies herein include hybrid and recombinant antibodies produced by splicing a variable (including hyperva ⁇ able) domain of an ant ⁇ -RP105 antibody with a constant domain (e g "humanized” antibodies), or a light chain with a heavy chain, or a chain from one species with a chain from another species, or fusions with heterologous proteins, regardless of species of origin or immunoglobulin class or subclass designation, as well as antibody fragments (e g , Fab, F(ab')2, and Fv), so long as they exhibit the desired biological activity (See, e g , Cabilly, et al , U S Pat No 4,816,567, Mage & Lamoyi, in Monoclonal Antibody Production Techniques and Applications, pp 79- 97 (Marcel Dekker, Inc , New York, 1987) )
  • the modifier "monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not
  • the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method described by Kohler and Milstein, supra, or may be made by recombinant DNA methods (Cabilly, et al., supra).
  • Humanized forms of non-human (e.g. murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab. Fab', F(ab')2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin.
  • humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity.
  • CDR complementary determining region
  • humanized antibody may comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. These modifications are made to further refine and optimize antibody performance.
  • the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence.
  • the humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
  • Fc immunoglobulin constant region
  • DNA encoding the monoclonal antibodies of the invention is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies).
  • the hybridoma cells of the invention serve as a preferred source of such DNA.
  • the DNA may be placed into expression vectors, which are then transfected into host cells such as simian COS cells. Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells.
  • the DNA also may be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences. Morrison, et al., Proc. Nat. Acad. Sci. 81, 6851 (1984), or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. In that manner, "chimeric" or “hybrid” antibodies are prepared that have the binding specificity of an anti RP105 monoclonal antibody herein.
  • non-immunoglobulin polypeptides are substituted for the constant domains of an antibody of this invention, or they are substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody comprising one antigen-combining bivalent antibody comprising one antigen- combining site having specificity for an RP105 and another antigen-combining site having specificity for a different antigen.
  • Chimeric or hybrid antibodies also may be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents.
  • immunotoxins may be constructed using a disulfide exchange reaction or by forming a thioether bond.
  • suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate.
  • a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import” variable domain. Humanization can be essentially performed following the method of Winter and co-workers (Jones et al., Nature 321 : 522-525 (1986); Riechmann et al., Nature 332, 323- 327 (1988); Verhoeyen et al., Science 239, 1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody.
  • humanized antibodies are chimeric antibodies (Cabilly, supra), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species.
  • humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.
  • humanized antibodies are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three dimensional models of the parental and humanized sequences.
  • Three dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art.
  • Computer programs are available which illustrate and display probably three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen.
  • FR residues can be selected and combined from the consensus and import sequence so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved.
  • the CDR residues are directly and most substantially involved in influencing antigen binding.
  • transgenic animals e.g., mice
  • transgenic animals e.g., mice
  • J antibody heavy chain joining region
  • the cells expressing the desired antibody can be isolated from the animal host and used to produce the antibody in cell culture, and the antibody can be harvested from the cell culture by standard methods.
  • Therapeutic Compositions and Administration of Anti-RP 105 Antibodies are prepared for storage by mixing antibody having the desired degree of purity with optional physiologically acceptable carriers, excipients, or stabilizers (Remington 's Pharmaceutical Sciences, supra), in the form of lyophilized cake or aqueous solutions.
  • Acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids, antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins, hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, aspargine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol, salt- forming couterions such as sodium; and/or nonionic surfactants such as Tween, Pluronics or polyethylene glycol (PEG).
  • buffers such as phosphate, citrate, and other organic acids, antioxidants including ascorbic acid
  • the anti-RP105 antibody to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes, prior to or following lyophilization and reconstitution.
  • the anti-RP105 antibody ordinarily will be stored in lyophilized form or in solution.
  • Therapeutic anti-RP105 antibody compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.
  • the route of anti-RP105 antibody administration is in accord with known methods, e.g., injection or infusion by intravenous, intraperitoneal, intercerebral, intramuscular, intraocular, intraarterial, intracerebrospinal, or intralesional routes, or by sustained release systems as noted below.
  • the antibody is given systemically.
  • sustained-release preparations include semipermeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules.
  • Sustained release matrices include polyesters, hydrogels, polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma ethyl-L-glutamate (Sidman et al., Biopolymers, 23: 547-556 (1983)), poly (2-hydroxyethylmethacrylate)(Langer et al., J. Biomed. Mater. Res. 15: 167-277 (1981) and Langer, Chem.
  • Sustained-release anti-RP105 antibody compositions also include liposomally entrapped antibody. Liposomes containing antibody are prepared by methods known per se: DE 3,218,121 ; Epstein et al., Proc. Natl. Acad. Sci. USA, 11: 4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641 ; Japanese patent application 83- 118008; U.S. Pat. Nos.
  • the liposomes are of the small (about 200-800 Angstroms) unilamelar type in which the lipid content is greater than about 30 mol % cholesterol, the selected proportion being adjusted for the optimal antibody therapy.
  • Anti-RP105 antibody can also be administered by inhalation.
  • Commercially available neublizers for liquid formulations including jet nebulizers and ultrasonic nebulizers are useful for administration.
  • Liquid formulations can be directly nebulized and lyophilized powder can be nebulized after reconstitution.
  • anti-RP105 antibody can be aerosolized using a fluorocarbon formulation and a metered dose inhaler, or inhaled as a lyophilized and milled powder.
  • an "effective amount" of anti-RP105 antibody to be employed therapeutically will depend, for example, upon the therapeutic objectives, the route of administration, the type of anti-RP105 antibody employed, and the condition of the patient. Accordingly, it will be necessary for the therapist to titer the dosage and modify the route of administration as required to obtain the optimal therapeutic effect. Typically, the clinician will administer the anti-RP105 antibody until a dosage is reached that achieves the desired effect. The progress of this therapy is easily monitored by conventional assays.
  • B cell neoplasms including chronic lymphocyte leukemia, hairy cell leukemia, prolymphocytic leukemia myelomas, autoimmune diseases such as systemic lupus Erythamatosus (SLE), rheumatoid arthritis(RA), Multiple Sclerosis (MS), aquired hemolytic anemia and diabetes in a mammal using an antibody to RP105 receptor by an anti-RP105 antibody
  • SLE systemic lupus Erythamatosus
  • RA rheumatoid arthritis
  • MS Multiple Sclerosis
  • aquired hemolytic anemia and diabetes in a mammal using an antibody to RP105 receptor by an anti-RP105 antibody the antibody composition will be formulated, dosed, and administered in a fashion consistent with good medical practice.
  • Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the antibody, the particular type of antibody, the method of administration, the scheduling of administration, and other factors known to medical practitioners.
  • the "therapeutically effective amount" of antibody to be administered will be governed by such considerations, and is the minimum amount necessary to prevent, ameliorate, or treat allergic disease, including asthma and atopic dermatitis, B cell neoplasms, including chronic lymphocyte leukemia, hairy cell leukemia, prolymphocytic leukemia myelomas, autoimmune diseases such as systemic lupus Erythamatosus (SLE), rheumatoid arthritis(RA), Multiple Sclerosis (MS), aquired hemolytic anemia and diabetes in a mammal using an antibody to RP105 receptor. Such amount is preferably below the amount that is toxic to the host.
  • the initial pharmaceutically effective amount of the antibody administered parenterally will be in the range of about 0.1 to 50 mg/kg of patient body weight per day, with the typical initial range of antibody used being 0.3 to 20 mg/kg/day, more preferably 0.3 to 15 mg/kg/day.
  • the desired dosage can be delivered by a single bolus, by multiple bolus administration, or by continuous infusion administration of antibody, depending on the pattern of pharmacokinetic decay that the practitioner wishes to achieve.
  • the antibody need not be, but is optionally formulated with one or more agents currently used to prevent or treat the allergic disease, including asthma and atopic dermatitis, B cell neoplasms, including chronic lymphocyte leukemia, hairy cell leukemia, prolymphocytic leukemia, myelomas, autoimmune diseases such as systemic lupus Erythamatosus (SLE), rheumatoid arthritis(RA), Multiple Sclerosis (MS), aquired hemolytic anemia and diabetes in a mammal using an antibody to RP105 receptor in question.
  • SLE systemic lupus Erythamatosus
  • RA rheumatoid arthritis
  • MS Multiple Sclerosis
  • aquired hemolytic anemia and diabetes in a mammal using an antibody to RP105 receptor in question.
  • the effective amount of such other agents depends on the amount of anti-RP105 antibody present in the formulation, the type of disorder or treatment, and other factors discussed above. These are generally used in
  • Antiserum to human RP105 was generated in mice by genetic immunization using a full length RP105 expression vector. This antiserum was used to characterize the function of RP105 in B lymphocyte responses. More specifically , peripheral blood lymphocytes were purified by differential density gradient purification. Diluted whole blood was layered onto Ficoll gradients (Pharmacia LKB Biotech, Piscataway, NJ) and centrifuged at 400xg for 30 minutes at 22oC. Cells were recovered from the interface of the gradient and washed twice in RPMI 1640 medium (Life technologies Inc., Gaithersburg, MA).
  • PBLs were adjusted to 2x106 cells/ml in RPMI 1640 medium supplemented with 10% Foetal Bovine Serum (Hyclone Laboratories, Logan, UT), 25mM Hepes buffer, 2mM L-Glutamine and 50ug/ml Gentomycin (Life Technologies Inc., Gaithersburg, MA).
  • lOOul of cell suspension was added to wells of a 96 well flat bottomed microtitre plate (Falcon Labware, Franklin Lakes, NJ) and 50ul of diluted mouse antiserum to human RP105 or control mouse antiserum were added to the cells. A further 50ul of medium were added to the wells and cells were incubated at 37 oC in 5% C02 for 66 hours.
  • B lymphocytes results in increased B cell proliferation, expression of co-stimulatory molecules, production of cytokines, differentiation, production of immunoglobulins and resistance to apoptosis RP105 receptor stimulation with specific antiserum resulted in B cell activation with increased proliferation
  • inhibition of RP105 signalling using blocking RP105 antibodies will inhibit B cell activation and thereby decrease antibody production and the capacity of B cells to present antigen to T cells
  • the capacity of RP105 to stimulate B cell proliferation and protection from apoptosis may be a mechanism of survival for chronically activated B cells as well as B lymphocyte neoplasms such as
  • Stimulatory RP105 antibodies that induce receptor signaling may also be used to screen for inhibitors (antagonists), which include both small molecular weight compounds and even blocking RP105 antibodies, of the RP105 signaling pathway
  • inhibitors include both small molecular weight compounds and even blocking RP105 antibodies, of the RP105 signaling pathway
  • the antagonist thus discovered will have utility in treating immune disorders where chronic activation of B cells results m the production of antibodies to allergemc proteins (asthma, allergic dermatitis, atopy) autoantibodies to self antigens (SLE, MS, RA) and diseases where B cells have been implicated in activation of T cells (RA, SLE, MS, diabetes)
  • the present invention relates to a method for identifying an antagonist of a RP105 which comprises contacting a cell expressing on the surface thereof a RP105 polypeptide, said RP105 polypeptide being associated with a second component capable of providing a detectable signal in response to a stimulatory RP105 antibody with a
  • a method for identifying an antagonist of a RP105 polypeptide comprises determining the inhibition of binding of a stimulatory RP105 antibody to cells which have the RP105 polypeptide on the surface thereof, or to cell membranes containing the polypeptide, in the presence of a candidate compound under conditions to permit binding to the polypeptide, and determining the amount of stimulatory RP105 antibody bound to the polypeptide, such that a compound capable of causing reduction of binding of stimulatory RP105 antibody is an antagonist
  • the present invention also relates to an antagonist obtainable by the above methods, and a method of treating immune disorders where chronic activation of B cells results in the production of antibodies to allergemc pioteins (asthma, allergic dermatitis, atopy) autoantibodies to self antigens (SLE, MS, RA) and diseases where B cells have been implicated in activation of T cells (RA, SLE, MS, diabetes) by administering to a patient suffering from such ailments by administering an effective amount of such antagonist
  • the present invention provides a method for treating or preventing allergic disease, including asthma and atopic dermatitis, B cell neoplasms, including chronic lymphocyte leukemia, hairy cell leukemia, prolymphocytic leukemia, myelomas, autoimmune diseases such as systemic lupus Erythamatosus (SLE), rheumatoid arth ⁇ t ⁇ s(RA), Multiple Sclerosis (MS), aquired hemolytic anemia or diabetes, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of antagonist of RP105
  • agonist RP105 mAbs similar to polyclonal antibodies demonstrated in Figure 1 would be expected to have utility in B cell immunodeficiencies resulting from bone marrow transplant, rheumatic illnesses or due to treatment for leukemia, and for example in primary immunodeficiency syndromes, Wolf-Hirschhorn syndrome, Nijmegen breakage syndrome and X-hnked agammaglobuhn
  • Agonists and antagonists of the present invention may be formulated in combination with a suitable pharmaceutical carrier
  • a suitable pharmaceutical carrier Such formulations comprise a therapeutically effective amount of an agonist or an antagonist, and a pharmaceutically acceptable earner or excipient
  • Such carriers include but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof Formulation should suit the mode of administration, and is well within the skill of the art
  • the invention further relates to pharmaceutical packs and kits comp ⁇ sing one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention
  • systemic administration of the pharmaceutical compositions include injection, typically by intravenous injection
  • Other injection routes such as subcutaneous, intramuscular, or lntrape ⁇ toneal
  • Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents
  • penetrants such as bile salts or fusidic acids or other detergents
  • oral administration may also be possible
  • Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels and the
  • the dosage range required depends on the choice of peptide, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner Suitable dosages, however, are in the range of 0 1-100 ⁇ g/kg of subject Wide vanations in the needed dosage, however, are to be expected in view of the variety of compounds available and the diffenng efficiencies of various routes of administration For example, oral administration would be expected to require higher dosages than administration by intravenous injection Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art All references cited in this specification are expressly incorporated by reference

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biophysics (AREA)

Abstract

L'invention concerne des procédés de traitement et de prévention de maladies allergiques au moyen d'antagonistes de RP105, ainsi que des procédés pour identifier des antagonistes de RP105.
PCT/US1999/019336 1998-08-27 1999-08-24 Agonistes et antagonistes de rp105 WO2000012130A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9803098P 1998-08-27 1998-08-27
US60/098,030 1998-08-27

Publications (1)

Publication Number Publication Date
WO2000012130A1 true WO2000012130A1 (fr) 2000-03-09

Family

ID=22266409

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/019336 WO2000012130A1 (fr) 1998-08-27 1999-08-24 Agonistes et antagonistes de rp105

Country Status (1)

Country Link
WO (1) WO2000012130A1 (fr)

Cited By (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049075A2 (fr) * 2003-11-17 2005-06-02 Genentech, Inc. Compositions et methodes de traitement d'une tumeur d'origine hematopoietique
WO2005110470A2 (fr) * 2004-04-16 2005-11-24 Children's Hospital Medical Center Procedes et compositions destinees a la modulation des reponses immunitaires et des maladies auto-immunes
WO2006102408A2 (fr) * 2005-03-22 2006-09-28 Children's Hospital Medical Center Methodes et compositions pour la modulation de reponses immunitaires et de maladies autoimmunes
EP2260858A2 (fr) 2003-11-06 2010-12-15 Seattle Genetics, Inc. Composés de monométhylvaline capable de conjugaison aux lignads.
EP2286844A2 (fr) 2004-06-01 2011-02-23 Genentech, Inc. Conjugués anticorps-médicament et procédés
WO2011031870A1 (fr) 2009-09-09 2011-03-17 Centrose, Llc Conjugués médicamenteux ciblés à visée extracellulaire
WO2011056983A1 (fr) 2009-11-05 2011-05-12 Genentech, Inc. Conjugués d'anticorps modifiés par cystéine, radiomarqués par le zirconium
WO2011130598A1 (fr) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazépines et conjugués de celles-ci
WO2011156328A1 (fr) 2010-06-08 2011-12-15 Genentech, Inc. Anticorps et conjugués modifiés par la cystéine
US8088378B2 (en) 2007-07-16 2012-01-03 Genetech Inc. Anti-CD79B antibodies and immunoconjugates and methods of use
WO2012074757A1 (fr) 2010-11-17 2012-06-07 Genentech, Inc. Conjugués d'anticorps alaninyl-maytansinol
US8226945B2 (en) 2006-05-30 2012-07-24 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
WO2012155019A1 (fr) 2011-05-12 2012-11-15 Genentech, Inc. Procédé lc-ms/ms de surveillance de réactions multiples pour détecter des anticorps thérapeutiques dans des échantillons animaux à l'aide de peptides de signature d'infrastructure
US8404656B2 (en) 2007-08-09 2013-03-26 Children's Hospital Medical Center Methods of treatment and prevention of diet-induced obesity and sequelae thereof
WO2013130093A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
WO2014057074A1 (fr) 2012-10-12 2014-04-17 Spirogen Sàrl Pyrrolobenzodiazépines et leurs conjugués
WO2014140174A1 (fr) 2013-03-13 2014-09-18 Spirogen Sàrl Pyrrolobenzodiazépines et leurs conjugués
WO2014140862A2 (fr) 2013-03-13 2014-09-18 Spirogen Sarl Pyrrolobenzodiazépines et leurs conjugués
WO2014159981A2 (fr) 2013-03-13 2014-10-02 Spirogen Sarl Pyrrolobenzodiazépines et leurs conjugués
WO2015023355A1 (fr) 2013-08-12 2015-02-19 Genentech, Inc. Conjugués anticorps-médicament dimérique 1-(chlorométhyl)-2,3-dihydro-1 h-benzo [e]indole, et méthodes d'utilisation et de traitement
WO2015095212A1 (fr) 2013-12-16 2015-06-25 Genentech, Inc. Composés conjugués anticorps-médicament dimérique à base de 1-(chlorométhyl)-2,3-dihydro-1 h-benzo [e]indole, et méthodes d'utilisation et de traitement
WO2015095223A2 (fr) 2013-12-16 2015-06-25 Genentech, Inc. Composés peptidomimétiques et conjugués anticorps-médicament de ceux-ci
WO2015095227A2 (fr) 2013-12-16 2015-06-25 Genentech, Inc. Composés peptidomimétiques et conjugués anticorps-médicament de ceux-ci
US9085630B2 (en) 2002-11-15 2015-07-21 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
WO2016040825A1 (fr) 2014-09-12 2016-03-17 Genentech, Inc. Intermédiaires disulfure d'anthracycline, conjugué anticorps-médicaments et procédés
WO2016040856A2 (fr) 2014-09-12 2016-03-17 Genentech, Inc. Anticorps et conjugués modifiés génétiquement avec de la cystéine
WO2016037644A1 (fr) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazépines et leurs conjugués
WO2016090050A1 (fr) 2014-12-03 2016-06-09 Genentech, Inc. Composés d'amine quaternaire et conjugués anticorps-médicament de ceux-ci
EP3088004A1 (fr) 2004-09-23 2016-11-02 Genentech, Inc. Anticorps et conjugués modifiés au niveau des cystéines
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
WO2017059289A1 (fr) 2015-10-02 2017-04-06 Genentech, Inc. Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
WO2017064675A1 (fr) 2015-10-16 2017-04-20 Genentech, Inc. Conjugués médicamenteux à pont disulfure encombré
WO2017068511A1 (fr) 2015-10-20 2017-04-27 Genentech, Inc. Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
WO2017165734A1 (fr) 2016-03-25 2017-09-28 Genentech, Inc. Dosage multiplexé pour la quantification d'anticorps totaux et de médicaments conjugués à des anticorps
EP3235820A1 (fr) 2014-09-17 2017-10-25 Genentech, Inc. Pyrrolobenzodiazépines et conjugués à base de disulfure d'anticorps associés
WO2017201449A1 (fr) 2016-05-20 2017-11-23 Genentech, Inc. Conjugués anticorps-protac et procédés d'utilisation
WO2017205741A1 (fr) 2016-05-27 2017-11-30 Genentech, Inc. Procédé bioanalytique pour la caractérisation de conjugués anticorps-médicament spécifiques d'un site
WO2017214024A1 (fr) 2016-06-06 2017-12-14 Genentech, Inc. Médicaments conjugués d'anticorps silvestrol et procédés d'utilisation
WO2018031662A1 (fr) 2016-08-11 2018-02-15 Genentech, Inc. Promédicaments de pyrrolobenzodiazépine et conjugués d'anticorps de ceux-ci
US9896506B2 (en) 2008-01-31 2018-02-20 Genentech, Inc. Anti-CD79B antibodies and immunoconjugates and methods of use
US9919056B2 (en) 2012-10-12 2018-03-20 Adc Therapeutics S.A. Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
US9931415B2 (en) 2012-10-12 2018-04-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9931414B2 (en) 2012-10-12 2018-04-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2018065501A1 (fr) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Procédés de préparation de conjugués anticorps-médicament
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US10029018B2 (en) 2013-10-11 2018-07-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2019060398A1 (fr) 2017-09-20 2019-03-28 Ph Pharma Co., Ltd. Analogues de thailanstatine
US10392393B2 (en) 2016-01-26 2019-08-27 Medimmune Limited Pyrrolobenzodiazepines
US10420777B2 (en) 2014-09-12 2019-09-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10544223B2 (en) 2017-04-20 2020-01-28 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
US10543279B2 (en) 2016-04-29 2020-01-28 Medimmune Limited Pyrrolobenzodiazepine conjugates and their use for the treatment of cancer
WO2020049286A1 (fr) 2018-09-03 2020-03-12 Femtogenix Limited Amides polycycliques servant d'agents cytotoxiques
WO2020086858A1 (fr) 2018-10-24 2020-04-30 Genentech, Inc. Inducteurs chimiques conjugués de dégradation et méthodes d'utilisation
WO2020123275A1 (fr) 2018-12-10 2020-06-18 Genentech, Inc. Peptides de photoréticulation pour conjugaison spécifique de site à des protéines contenant fc
US10695439B2 (en) 2016-02-10 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine conjugates
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2020157491A1 (fr) 2019-01-29 2020-08-06 Femtogenix Limited Agents cytotoxiques de réticulation g-a
US10736903B2 (en) 2012-10-12 2020-08-11 Medimmune Limited Pyrrolobenzodiazepine-anti-PSMA antibody conjugates
US10751346B2 (en) 2012-10-12 2020-08-25 Medimmune Limited Pyrrolobenzodiazepine—anti-PSMA antibody conjugates
US10780096B2 (en) 2014-11-25 2020-09-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
US10799595B2 (en) 2016-10-14 2020-10-13 Medimmune Limited Pyrrolobenzodiazepine conjugates
US10981987B2 (en) 2007-07-16 2021-04-20 Genentech, Inc. Humanized anti-CD79b antibodies and immunoconjugates and methods of use
US11000510B2 (en) 2014-09-23 2021-05-11 Genentech, Inc. Methods of using anti-CD79b immunoconjugates
US11059893B2 (en) 2015-04-15 2021-07-13 Bergenbio Asa Humanized anti-AXL antibodies
US11135303B2 (en) 2011-10-14 2021-10-05 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US11160872B2 (en) 2017-02-08 2021-11-02 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
US11318211B2 (en) 2017-06-14 2022-05-03 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
US11352324B2 (en) 2018-03-01 2022-06-07 Medimmune Limited Methods
US11370801B2 (en) 2017-04-18 2022-06-28 Medimmune Limited Pyrrolobenzodiazepine conjugates
US11517626B2 (en) 2016-02-10 2022-12-06 Medimmune Limited Pyrrolobenzodiazepine antibody conjugates
US11524969B2 (en) 2018-04-12 2022-12-13 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof as antitumour agents
US11612665B2 (en) 2017-02-08 2023-03-28 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US11649250B2 (en) 2017-08-18 2023-05-16 Medimmune Limited Pyrrolobenzodiazepine conjugates
US11702473B2 (en) 2015-04-15 2023-07-18 Medimmune Limited Site-specific antibody-drug conjugates
WO2024138128A2 (fr) 2022-12-23 2024-06-27 Genentech, Inc. Conjugués d'agent de dégradation de céréblon et leurs utilisations
WO2024220546A2 (fr) 2023-04-17 2024-10-24 Peak Bio, Inc. Anticorps et conjugués anticorps-médicament et procédés d'utilisation, processus synthétiques et intermédiaires

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780609A (en) * 1995-10-19 1998-07-14 Smithkline Beecham Corporation DNA sequence of human RP-105

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780609A (en) * 1995-10-19 1998-07-14 Smithkline Beecham Corporation DNA sequence of human RP-105

Cited By (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9085630B2 (en) 2002-11-15 2015-07-21 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
EP3858387A1 (fr) 2003-11-06 2021-08-04 Seagen Inc. Composés de monométhylvaline capables de conjugaison aux ligands
EP3120861A1 (fr) 2003-11-06 2017-01-25 Seattle Genetics, Inc. Composés intermédiaires pour la préparation de conjugués d'auristatin avec des éléments de liaison
EP2478912A1 (fr) 2003-11-06 2012-07-25 Seattle Genetics, Inc. Conjugués d'auristatin avec des anticorps dirigés contre le HER2 ou le CD22 et leur usage thérapeutique
EP3434275A1 (fr) 2003-11-06 2019-01-30 Seattle Genetics, Inc. Méthode de dépistage de cellules cancéreuses basé sur l'utilisation de conjugués d'auristatin avec anticorps
EP2489364A1 (fr) 2003-11-06 2012-08-22 Seattle Genetics, Inc. Composés de monométhylvaline conjuguös avec des anticorps
EP2260858A2 (fr) 2003-11-06 2010-12-15 Seattle Genetics, Inc. Composés de monométhylvaline capable de conjugaison aux lignads.
EP2486933A1 (fr) 2003-11-06 2012-08-15 Seattle Genetics, Inc. Composés de monométhylvaline conjugués avec des anticorps
AU2004291141B2 (en) * 2003-11-17 2009-06-11 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
WO2005049075A2 (fr) * 2003-11-17 2005-06-02 Genentech, Inc. Compositions et methodes de traitement d'une tumeur d'origine hematopoietique
JP2007516242A (ja) * 2003-11-17 2007-06-21 ジェネンテック・インコーポレーテッド 造血系起源の腫瘍の治療のための組成物と方法
JP4901478B2 (ja) * 2003-11-17 2012-03-21 ジェネンテック， インコーポレイテッド 造血系起源の腫瘍の治療のための組成物と方法
WO2005049075A3 (fr) * 2003-11-17 2005-11-10 Genentech Inc Compositions et methodes de traitement d'une tumeur d'origine hematopoietique
WO2005110470A2 (fr) * 2004-04-16 2005-11-24 Children's Hospital Medical Center Procedes et compositions destinees a la modulation des reponses immunitaires et des maladies auto-immunes
WO2005110470A3 (fr) * 2004-04-16 2006-08-03 Childrens Hosp Medical Center Procedes et compositions destinees a la modulation des reponses immunitaires et des maladies auto-immunes
EP2286844A2 (fr) 2004-06-01 2011-02-23 Genentech, Inc. Conjugués anticorps-médicament et procédés
EP3088004A1 (fr) 2004-09-23 2016-11-02 Genentech, Inc. Anticorps et conjugués modifiés au niveau des cystéines
WO2006102408A3 (fr) * 2005-03-22 2006-12-28 Childrens Hosp Medical Center Methodes et compositions pour la modulation de reponses immunitaires et de maladies autoimmunes
WO2006102408A2 (fr) * 2005-03-22 2006-09-28 Children's Hospital Medical Center Methodes et compositions pour la modulation de reponses immunitaires et de maladies autoimmunes
US8226945B2 (en) 2006-05-30 2012-07-24 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US8968741B2 (en) 2006-05-30 2015-03-03 Genentech, Inc. Anti-CD22 antibodies and immunoconjugates and methods of use
US8524865B2 (en) 2006-05-30 2013-09-03 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US8394607B2 (en) 2006-05-30 2013-03-12 Genentech, Inc. Anti-CD22 antibodies and immunoconjugates and methods of use
US8545850B2 (en) 2007-07-16 2013-10-01 Genentech, Inc. Anti-CD79B antibodies and immunoconjugates and methods of use
US10494432B2 (en) 2007-07-16 2019-12-03 Genentech, Inc. Anti-CD79B antibodies and immunoconjugates and methods of use
US8691531B2 (en) 2007-07-16 2014-04-08 Genentech, Inc. Anti-CD79B antibodies and immunoconjugates and methods of use
US11866496B2 (en) 2007-07-16 2024-01-09 Genentech, Inc. Humanized anti-CD79B antibodies and immunoconjugates and methods of use
US8088378B2 (en) 2007-07-16 2012-01-03 Genetech Inc. Anti-CD79B antibodies and immunoconjugates and methods of use
USRE48558E1 (en) 2007-07-16 2021-05-18 Genentech, Inc. Anti-CD79B antibodies and immunoconjugates and methods of use
US10981987B2 (en) 2007-07-16 2021-04-20 Genentech, Inc. Humanized anti-CD79b antibodies and immunoconjugates and methods of use
US8404656B2 (en) 2007-08-09 2013-03-26 Children's Hospital Medical Center Methods of treatment and prevention of diet-induced obesity and sequelae thereof
US10544218B2 (en) 2008-01-31 2020-01-28 Genentech, Inc. Anti-CD79B antibodies and immunoconjugates and methods of use
US9896506B2 (en) 2008-01-31 2018-02-20 Genentech, Inc. Anti-CD79B antibodies and immunoconjugates and methods of use
WO2011031870A1 (fr) 2009-09-09 2011-03-17 Centrose, Llc Conjugués médicamenteux ciblés à visée extracellulaire
WO2011056983A1 (fr) 2009-11-05 2011-05-12 Genentech, Inc. Conjugués d'anticorps modifiés par cystéine, radiomarqués par le zirconium
WO2011130598A1 (fr) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazépines et conjugués de celles-ci
WO2011156328A1 (fr) 2010-06-08 2011-12-15 Genentech, Inc. Anticorps et conjugués modifiés par la cystéine
WO2012074757A1 (fr) 2010-11-17 2012-06-07 Genentech, Inc. Conjugués d'anticorps alaninyl-maytansinol
WO2012155019A1 (fr) 2011-05-12 2012-11-15 Genentech, Inc. Procédé lc-ms/ms de surveillance de réactions multiples pour détecter des anticorps thérapeutiques dans des échantillons animaux à l'aide de peptides de signature d'infrastructure
US11135303B2 (en) 2011-10-14 2021-10-05 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2013130093A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
US10799596B2 (en) 2012-10-12 2020-10-13 Adc Therapeutics S.A. Pyrrolobenzodiazepine-antibody conjugates
US10646584B2 (en) 2012-10-12 2020-05-12 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10994023B2 (en) 2012-10-12 2021-05-04 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP2839860A1 (fr) 2012-10-12 2015-02-25 Spirogen Sàrl Pyrrolobenzodiazépines et ses conjugués
US10780181B2 (en) 2012-10-12 2020-09-22 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US10751346B2 (en) 2012-10-12 2020-08-25 Medimmune Limited Pyrrolobenzodiazepine—anti-PSMA antibody conjugates
US10736903B2 (en) 2012-10-12 2020-08-11 Medimmune Limited Pyrrolobenzodiazepine-anti-PSMA antibody conjugates
US10722594B2 (en) 2012-10-12 2020-07-28 Adc Therapeutics S.A. Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US12121590B2 (en) 2012-10-12 2024-10-22 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US11690918B2 (en) 2012-10-12 2023-07-04 Medimmune Limited Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
US10335497B2 (en) 2012-10-12 2019-07-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2014057074A1 (fr) 2012-10-12 2014-04-17 Spirogen Sàrl Pyrrolobenzodiazépines et leurs conjugués
US11779650B2 (en) 2012-10-12 2023-10-10 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9889207B2 (en) 2012-10-12 2018-02-13 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US11771775B2 (en) 2012-10-12 2023-10-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US11701430B2 (en) 2012-10-12 2023-07-18 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9919056B2 (en) 2012-10-12 2018-03-20 Adc Therapeutics S.A. Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
US9931415B2 (en) 2012-10-12 2018-04-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9931414B2 (en) 2012-10-12 2018-04-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
WO2014140174A1 (fr) 2013-03-13 2014-09-18 Spirogen Sàrl Pyrrolobenzodiazépines et leurs conjugués
WO2014140862A2 (fr) 2013-03-13 2014-09-18 Spirogen Sarl Pyrrolobenzodiazépines et leurs conjugués
WO2014159981A2 (fr) 2013-03-13 2014-10-02 Spirogen Sarl Pyrrolobenzodiazépines et leurs conjugués
WO2015023355A1 (fr) 2013-08-12 2015-02-19 Genentech, Inc. Conjugués anticorps-médicament dimérique 1-(chlorométhyl)-2,3-dihydro-1 h-benzo [e]indole, et méthodes d'utilisation et de traitement
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US10029018B2 (en) 2013-10-11 2018-07-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015095227A2 (fr) 2013-12-16 2015-06-25 Genentech, Inc. Composés peptidomimétiques et conjugués anticorps-médicament de ceux-ci
WO2015095212A1 (fr) 2013-12-16 2015-06-25 Genentech, Inc. Composés conjugués anticorps-médicament dimérique à base de 1-(chlorométhyl)-2,3-dihydro-1 h-benzo [e]indole, et méthodes d'utilisation et de traitement
WO2015095223A2 (fr) 2013-12-16 2015-06-25 Genentech, Inc. Composés peptidomimétiques et conjugués anticorps-médicament de ceux-ci
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2016037644A1 (fr) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazépines et leurs conjugués
US10420777B2 (en) 2014-09-12 2019-09-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2016040856A2 (fr) 2014-09-12 2016-03-17 Genentech, Inc. Anticorps et conjugués modifiés génétiquement avec de la cystéine
WO2016040825A1 (fr) 2014-09-12 2016-03-17 Genentech, Inc. Intermédiaires disulfure d'anthracycline, conjugué anticorps-médicaments et procédés
EP3235820A1 (fr) 2014-09-17 2017-10-25 Genentech, Inc. Pyrrolobenzodiazépines et conjugués à base de disulfure d'anticorps associés
US12016842B2 (en) 2014-09-23 2024-06-25 Genentech, Inc. Methods of using anti-CD79b immunoconjugates
US11000510B2 (en) 2014-09-23 2021-05-11 Genentech, Inc. Methods of using anti-CD79b immunoconjugates
US10780096B2 (en) 2014-11-25 2020-09-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
WO2016090050A1 (fr) 2014-12-03 2016-06-09 Genentech, Inc. Composés d'amine quaternaire et conjugués anticorps-médicament de ceux-ci
US11702473B2 (en) 2015-04-15 2023-07-18 Medimmune Limited Site-specific antibody-drug conjugates
US11059893B2 (en) 2015-04-15 2021-07-13 Bergenbio Asa Humanized anti-AXL antibodies
WO2017059289A1 (fr) 2015-10-02 2017-04-06 Genentech, Inc. Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
WO2017064675A1 (fr) 2015-10-16 2017-04-20 Genentech, Inc. Conjugués médicamenteux à pont disulfure encombré
WO2017068511A1 (fr) 2015-10-20 2017-04-27 Genentech, Inc. Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
US10392393B2 (en) 2016-01-26 2019-08-27 Medimmune Limited Pyrrolobenzodiazepines
US10695439B2 (en) 2016-02-10 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine conjugates
US11517626B2 (en) 2016-02-10 2022-12-06 Medimmune Limited Pyrrolobenzodiazepine antibody conjugates
WO2017165734A1 (fr) 2016-03-25 2017-09-28 Genentech, Inc. Dosage multiplexé pour la quantification d'anticorps totaux et de médicaments conjugués à des anticorps
EP4273551A2 (fr) 2016-03-25 2023-11-08 F. Hoffmann-La Roche AG Dosage multiplexé pour la quantification d'anticorps totaux et de médicaments conjugués à des anticorps
US10543279B2 (en) 2016-04-29 2020-01-28 Medimmune Limited Pyrrolobenzodiazepine conjugates and their use for the treatment of cancer
WO2017201449A1 (fr) 2016-05-20 2017-11-23 Genentech, Inc. Conjugués anticorps-protac et procédés d'utilisation
WO2017205741A1 (fr) 2016-05-27 2017-11-30 Genentech, Inc. Procédé bioanalytique pour la caractérisation de conjugués anticorps-médicament spécifiques d'un site
WO2017214024A1 (fr) 2016-06-06 2017-12-14 Genentech, Inc. Médicaments conjugués d'anticorps silvestrol et procédés d'utilisation
WO2018031662A1 (fr) 2016-08-11 2018-02-15 Genentech, Inc. Promédicaments de pyrrolobenzodiazépine et conjugués d'anticorps de ceux-ci
WO2018065501A1 (fr) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Procédés de préparation de conjugués anticorps-médicament
US10799595B2 (en) 2016-10-14 2020-10-13 Medimmune Limited Pyrrolobenzodiazepine conjugates
US11160872B2 (en) 2017-02-08 2021-11-02 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
US11612665B2 (en) 2017-02-08 2023-03-28 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US11813335B2 (en) 2017-02-08 2023-11-14 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US11370801B2 (en) 2017-04-18 2022-06-28 Medimmune Limited Pyrrolobenzodiazepine conjugates
US10544223B2 (en) 2017-04-20 2020-01-28 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
US11938192B2 (en) 2017-06-14 2024-03-26 Medimmune Limited Dosage regimes for the administration of an anti-CD19 ADC
US11318211B2 (en) 2017-06-14 2022-05-03 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
US11649250B2 (en) 2017-08-18 2023-05-16 Medimmune Limited Pyrrolobenzodiazepine conjugates
WO2019060398A1 (fr) 2017-09-20 2019-03-28 Ph Pharma Co., Ltd. Analogues de thailanstatine
US11352324B2 (en) 2018-03-01 2022-06-07 Medimmune Limited Methods
US11524969B2 (en) 2018-04-12 2022-12-13 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof as antitumour agents
WO2020049286A1 (fr) 2018-09-03 2020-03-12 Femtogenix Limited Amides polycycliques servant d'agents cytotoxiques
WO2020086858A1 (fr) 2018-10-24 2020-04-30 Genentech, Inc. Inducteurs chimiques conjugués de dégradation et méthodes d'utilisation
WO2020123275A1 (fr) 2018-12-10 2020-06-18 Genentech, Inc. Peptides de photoréticulation pour conjugaison spécifique de site à des protéines contenant fc
WO2020157491A1 (fr) 2019-01-29 2020-08-06 Femtogenix Limited Agents cytotoxiques de réticulation g-a
WO2024138128A2 (fr) 2022-12-23 2024-06-27 Genentech, Inc. Conjugués d'agent de dégradation de céréblon et leurs utilisations
WO2024220546A2 (fr) 2023-04-17 2024-10-24 Peak Bio, Inc. Anticorps et conjugués anticorps-médicament et procédés d'utilisation, processus synthétiques et intermédiaires

Similar Documents

Publication Publication Date Title
WO2000012130A1 (fr) Agonistes et antagonistes de rp105
RU2082428C1 (ru) СПОСОБ ПОЛУЧЕНИЯ АНТИТЕЛ, СПЕЦИФИЧЕСКИ СВЯЗЫВАЮЩИХСЯ С Ig E
US7098184B2 (en) Method of treating rheumatoid arthritis and multiple sclerosis diseases of the human immune system
EP0726952B1 (fr) Recepteur situe sur la surface de lymphocytes t actives, appele act-4
US6458360B1 (en) Soluble complement regulatory molecules
US20110177093A1 (en) Use of bcma as an immunoregulatory agent
Bikah et al. A role for CD5 in cognate interactions between T cells and B cells, and identification of a novel ligand for CD5.
KR20010101987A (ko) 면역 반응과 관련된 신규한 폴리펩티드
PL207501B1 (pl) Zastosowanie polipeptydu BCMA oraz przeciwciała skierowanego przeciwko BCMA
JP2000514281A (ja) ヒトｂ細胞抗原；関連する試薬
AU7713098A (en) Ntn-2 member of tnf ligand family
AU7608898A (en) Ntn-2 member of tnf ligand family
US20030044416A1 (en) Nucleic acids encoding cd100 molecules
KR100398819B1 (ko) gp39길항제를포함하는약제조성물
AU8767698A (en) Novel orphan receptor
US20020123617A1 (en) Novel immunoglobulin superfamily members of APEX-1, APEX-2 and APEX-3 and uses thereof
US7622554B2 (en) FAS ligand derived polypeptides
US20210388100A1 (en) Compositions and methods regarding engineered and non-engineered gamma delta t-cells for treatment of hematological tumors
JPH11225774A (ja) 免疫グロブリン遺伝子スーパーファミリーのメンバー、ｐｉｇｒ−１
CA2346496A1 (fr) Nouvelles molecules specifiques de th2 et leurs utilisations
AU1422099A (en) Methods of prolonged suppression of humoral immunity
JPH03169896A (ja) 脳因子
RU2186783C2 (ru) Кроличья антисыворотка, ингибирующая транспорт катионных аминокислот, и содержащая ее фармацевтическая композиция
PL193670B1 (pl) Sposób przygotowania bydlęcego CD14 z serwatki siary bydlęcej, sposób bezpośredniej aktywacji komórek B in vitro, sposób bezpośredniej indukcji wzrostu i różnicowania komórek B in vitro do komórek wydzielających immunoglobulinę na wysokim poziomie, sposób przygotowania czystego białka lub ko-i/lub posttranslacyjnie zmodyfikowanej postaci białka, zastosowanie polipeptydu, sposób wytwarzania mieszanki dla niemowląt, sposób wytwarzania szczepionki oraz zestaw do przygotowania szczepienia
EP0915155A1 (fr) Nouveau transducteur de signaux

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase